Document is current
Any future updates will be listed below
-
Authors
Schleenvoigt, Benjamin T.
Ankert, Juliane
Barten-Neiner, Grit
Voit, Florian
Suttorp, Norbert
Boesecke, Christoph
Hoffmann, Christian
Stolz, Daiana
Pletz, Mathias W.
Rohde, Gernot
Witzenrath, Martin
Panning, Marcus
Essig, Andreas
Rupp, Jan
Degen, Olaf
Stephan, Christoph
,
Dreher, M.
Cornelissen, C.
Knüppel, W.
Creutz, P.
Mikolajewska, A.
le Claire, A.
Benzke, M.
Bauer, T.
Krieger, D.
Prediger, M.
Schmager, S.
Kolditz, M.
Schulte-Hubbert, B.
Langner, S.
Hüfner, A.
Welte, T.
Freise, J.
Nawrocki, M.
Fuge, I.
Freise, J.
Naim, J.
Kröner, W.
Illig, T.
Klopp, N.
Kroegel, C.
Moeser, A.
Bahrs, C.
Drömann, D.
Parschke, P.
Franzen, K.
Käding, N.
Wouters, M.
Walraven, K.
Braeken, D.
Buschmann, H.
Zaruchas, A.
Schaberg, T.
Hering, I.
Albrich, W.
Waldeck, F.
Rassouli, F.
Baldesberger, S.
Wallner, M.
-
Funding
Funding for this research was provided by:
German Federal Ministry of Education and Research grant (01KI07145)
German Center for Lung Research (82DZL00204)
Deutsches Zentrum für Lungenforschung (82DZL002A4)
Friedrich-Schiller-Universität Jena
- License Information
-
More Information
Article History
Received: 26 February 2023
Accepted: 26 June 2023
First Online: 9 July 2023
Declarations
:
: Some of the authors have conflicts of interest. If the manuscript is accepted for publication by Infection, these will be specified in detail.
: B.T. Schleenvoigt received fees and financial support from the Central German Working group HIV e. V., Gilead, MSD, Janssen-Cilag, Pfizer, CRM, Falk, AstraZeneca, ViiV, AIDS help Potsdam, AIDS help Dresden and Merck outside of the present work. G. Barten-Neiner received funding for CAPNETZ from German Lung Center (DZL) and Grants from Pfizer. F. Voit received fees and financial support from B. Braun Melsungen AG, MSD and Gilead outside of the present work. C. Boesecke received financial research grants from DZIF, NEAT ID, Hector foundation and honoraria from Abbvie, MSD, JnJ, Gilead and ViiV outside of the present work. M. W. Pletz received financial research support from Infectopharm and Pfizer and honoraria from MSD, Pfizer, Shionogi, Bayer, Sanofi, GSK, Thermofisher and Roche outside of the present work. M. Witzenrath received financial research support from DFG, Bundesministerium für Bildung und Forschung, Deutsche Gesellschaft für Pneumologie, European Respiratory Society, Marie Curie Foundation, Else Kröner Fresenius Stiftung, Capnetz Stiftung, Bayer Health Care, Biotest and honoraria from Astrazeneca, Insmed, Chiesi, Novartis, Teva, Actelion, Boehringer Ingelheim, GSK, Biotest, Bayer Health Care, Pantherna, Pherecydes, and Inflarx outside of the present work. C. Stephan received honoraria from Gilead, MSD, Janssen-Cilag, AbbVie, ViiV and TAD outside the present work. None competing interests for J. Ankert, N. Suttorp, C. Hoffmann, D. Stolz, G. Rohde, A. Essig, M. Panning, J. Rupp, O. Degen.
: CAPNETZ is a national German cross-sectional and observational study, prospectively enrolling patients since 2001, and was approved by leading ethics committee (EC) Hanover Medical School (Vote-No. 601–2008) and by all locally involved EC. HIV/CAP was amended as CAPNETZ substudy in 2017 to enroll HIV-positive individuals. Written informed consent was obtained from all patients admitted, and all were treated according to the Declaration of Helsinki, national and institutional standards.
